Why highly proliferative pancreatic neuroendocrine‐like tumours require dual lineage assessment
Histopathology · 2026-06 · 88 (7) · 1464-1465
DOI: 10.1111/his.70134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 09.03.2026. Verfasst von Sunder Sham und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Sunder Sham, Qingqing Liu
Zitieren
APA
Sham, S., & Liu, Q. (2026). Why highly proliferative pancreatic neuroendocrine‐like tumours require dual lineage assessment. Histopathology, 88(7), 1464-1465. https://doi.org/10.1111/his.70134
Vancouver
Sham S, Liu Q. Why highly proliferative pancreatic neuroendocrine‐like tumours require dual lineage assessment. Histopathology. 2026;88(7):1464-1465. doi:10.1111/his.70134
BibTeX
@article{Sham2026,
author = {Sham, Sunder and Liu, Qingqing},
title = {Why highly proliferative pancreatic neuroendocrine‐like tumours require dual lineage assessment},
journal = {Histopathology},
year = {2026},
volume = {88},
number = {7},
pages = {1464--1465},
doi = {10.1111/his.70134}
}
EUVIMED